Press Detail

Biotest AG opens 11th plasma collection centre in Germany

EQS-News: Biotest AG / Key word(s): Miscellaneous
Biotest AG opens 11th plasma collection centre in Germany
18.01.2024 / 08:00 CET/CEST
The issuer is solely responsible for the content of this announcement.








Biotest AG opens 11th plasma collection centre in Germany


  • 37 plasma collection centres in Europe to secure long term plasma supply

Dreieich, 18 January 2024. Biotest has officially opened the 11th plasma collection centre in Germany in Cologne.

In the ultra-modern centre on Wiener Platz in Cologne-Mülheim, plasma donors can now donate plasma five days a week, Monday to Friday. Friendly and dedicated staff offer an excellent service for sustainable and paperless plasma donation. The new centre is operated by Plasma Service Europe GmbH, a wholly owned subsidiary of Biotest AG, which was founded more than 20 years ago to strengthen plasma donation in Germany.

"In our second centre in Cologne, we are creating 20 new, highly qualified jobs. We are particularly pleased that we can now also offer donors in Cologne on the right bank of the Rhine the opportunity to donate plasma close to where they live," says centre director Faried Hussein.

"Our thanks go to our dedicated team, the construction companies involved and the architects for realizing the project in these challenging times. Of course, we also hope for many new donors who will join us in ensuring the supply of life-saving medicines to patients worldwide," emphasizes Henrik Oehme, Managing Director of Plasma Service Europe GmbH.

Together with State Secretary Matthias Heidmeier, District Mayor Norbert Fuchs and other political and business representatives, the managing directors of Plasma Service Europe GmbH, Marina Hohenböken and Henrik Oehme, opened the plasma donation centre in Cologne-Mülheim. "Together we are creating a strong foundation for improved medical care and helping to save lives. I wish the plasma centre a successful start and am confident that it will make a lasting contribution to the healthcare of our population," said Matthias Heidmeier, State Secretary in the Ministry of Labour, Health and Social Affairs of the State of North Rhine-Westphalia.

In addition to the management of Plasma Service Europe GmbH, patient representatives from dsai e.V., a patient organization for congenital immunodeficiencies, were also available for moving reports and testimonials about plasma donation. Silke Junge-Unbehauen, for example, is one of more than four million people affected in Germany. The young woman suffers from an antibody deficiency syndrome and is dependent on medication from blood plasma: "When I was diagnosed with the immunodeficiency (CVID) in 2013, I was of course totally unsure what to do next. Then I was put on a medication that is made from blood plasma. I can't thank the plasma donors often enough. They make my life worth living."

Biotest is thus continuing the planned expansion of its own donation centres in Europe in order to contribute to more plasma donations after the corona pandemic has shown how much Germany and Europe depend on plasma donations from outside the EU.

The collected plasma is processed exclusively in Germany at Biotest AG in Dreieich. Regular audits in Germany ensure that the high legal and internal quality and safety requirements are met.



About human blood plasma

Human blood plasma is a raw material used to produce plasma derived products, which are used to treat various illnesses of the immune system, the blood system, as well as in emergency medicine. Biotest ranks as one of the world's sixth largest plasma protein product manufacturing groups. Biotest is one of the world's six largest manufacturers of plasma protein products.



About Biotest

Biotest is a provider of biological therapeutics derived from human plasma. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive care medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. Biotest has more than 2,400 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange.




IR contact

Dr Monika Baumann (Buttkereit)

Phone: +49-6103-801-4406


PR contact

Dirk Neumüller

Phone: +49-6103-801-269


Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany,


Ordinary shares: securities’ ID No. 522720; ISIN DE0005227201

Preference shares: securities’ ID No. 522723; ISIN DE0005227235

Listing: Frankfurt (Prime Standard)

Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, Tradegate

This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.


18.01.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

show this